{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:52:54Z","timestamp":1762005174444,"version":"build-2065373602"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T00:00:00Z","timestamp":1520208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10157-018-1545-7","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T04:23:10Z","timestamp":1520223790000},"page":"1079-1087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD)"],"prefix":"10.1007","volume":"22","author":[{"given":"Shiho","family":"Makabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Mitobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"issue":"3","key":"1545_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","volume":"17","author":"T Mochizuki","year":"2013","unstructured":"Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2013;17(3):317\u201326. \n                    https:\/\/doi.org\/10.1007\/s10157-012-0741-0\n                    \n                  .","journal-title":"Clin Exp Nephrol"},{"issue":"10","key":"1545_CR2","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone","year":"2003","unstructured":"Gattone VH, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9(10):1323\u20136. \n                    https:\/\/doi.org\/10.1038\/nm935\n                    \n                  .","journal-title":"Nat Med"},{"issue":"25","key":"1545_CR3","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1205511\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"11","key":"1545_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38(11):1103\u201313. \n                    https:\/\/doi.org\/10.1007\/s40264-015-0327-3\n                    \n                  .","journal-title":"Drug Saf"},{"key":"1545_CR5","unstructured":"SAMSCA\u00ae (tolvaptan) Package insert [in Japanese], revised Mar 2017. 2018. \n                    http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/180078_2139011D1022_1_01.pdf\n                    \n                  ."},{"key":"1545_CR6","unstructured":"JINARC\u2122 (tolvaptan) Product Monograph, Otsuka Canada Pharmaceutical Inc. 2018. \n                    http:\/\/otsukacanada.com\/docs\/default-source\/default-document-library\/jinarc-pm-en-23feb2015_final.pdf?sfvrsn=2\n                    \n                  ."},{"issue":"3","key":"1545_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00000658-199703000-00008","volume":"225","author":"JF Gigot","year":"1997","unstructured":"Gigot JF, Jadoul P, Que F, Van Beers BE, Etienne J, Horsmans Y, et al. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? Ann Surg. 1997;225(3):286\u201394.","journal-title":"Ann Surg"},{"key":"1545_CR8","unstructured":"United States Food and Drug Administration. Guidance for industry, drug-induced liver injury: premarketing clinical evaluation. 2014. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdf\n                    \n                  . Accessed 11 Feb 2015."},{"issue":"1","key":"1545_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4168\/aair.2016.8.1.3","volume":"8","author":"SH Kim","year":"2016","unstructured":"Kim SH, Naisbitt DJ. Update on advances in research on idiosyncratic drug-induced liver injury. Allergy Asthma Immunol Res. 2016;8(1):3\u201311. \n                    https:\/\/doi.org\/10.4168\/aair.2016.8.1.3\n                    \n                  .","journal-title":"Allergy Asthma Immunol Res"},{"issue":"1","key":"1545_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.dmpk.2016.11.008","volume":"32","author":"JL Woodhead","year":"2017","unstructured":"Woodhead JL, Watkins PB, Howell BA, Siler SQ, Shoda LKM. The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. Drug Metab Pharmacokinet. 2017;32(1):40 \u2013 5. \n                    https:\/\/doi.org\/10.1016\/j.dmpk.2016.11.008\n                    \n                  .","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"1545_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/liv.12988","volume":"36","author":"L Dara","year":"2016","unstructured":"Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36(2):158\u201365. \n                    https:\/\/doi.org\/10.1111\/liv.12988\n                    \n                  .","journal-title":"Liver Int"},{"issue":"1","key":"1545_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","volume":"155","author":"JL Woodhead","year":"2017","unstructured":"Woodhead JL, Brock WJ, Roth SE, Shoaf SE, Brouwer KL, Church R, et al. Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicol Sci. 2017;155(1):61\u201374. \n                    https:\/\/doi.org\/10.1093\/toxsci\/kfw193\n                    \n                  .","journal-title":"Toxicol Sci"},{"issue":"1","key":"1545_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/toxsci\/kfv231","volume":"149","author":"JR Slizgi","year":"2016","unstructured":"Slizgi JR, Lu Y, Brouwer KR, St Claire RL, Freeman KM, Pan M, et al. Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites: contributing factors to drug-induced liver injury? Toxicol Sci. 2016;149(1):237\u201350. \n                    https:\/\/doi.org\/10.1093\/toxsci\/kfv231\n                    \n                  .","journal-title":"Toxicol Sci"},{"issue":"2","key":"1545_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/toxsci\/kfw269","volume":"156","author":"M Mosedale","year":"2017","unstructured":"Mosedale M, Kim Y, Brock WJ, Roth SE, Wiltshire T, Eaddy JS et al. Editor\u2019s highlight: candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach. Toxicol Sci. 2017;156(2):438 \u2013 54. \n                    https:\/\/doi.org\/10.1093\/toxsci\/kfw269\n                    \n                  .","journal-title":"Toxicol Sci"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1545-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1545-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1545-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T19:23:55Z","timestamp":1553714635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1545-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1545-7","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2018,3,5]]},"assertion":[{"value":"23 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Toshio Mochizuki and Ken Tsuchiya received Travel fees and honoraria for lectures from Otsuka Pharmaceutical Co. Toshio Mochizuki and Hiroshi Kataoka belong to an endowed department sponsored by Otsuka Pharmaceutical Co, Chugai Pharmaceutical Co, Kyowa Hakko Kirin Co, MSD Co, and JMS Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number 140807) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}